Has Wegovy killed anyone? What the evidence shows

Did anyone die in the clinical trials for Wegovy?

The trial most people point to is STEP 1, published in the New England Journal of Medicine in 2021. It enrolled adults with obesity and followed them for 68 weeks. Deaths did occur in both the semaglutide group and the placebo group during the trial, which is expected in any large, long-running study of adults with obesity-related health conditions. Crucially, the trial investigators and regulators did not find a causal link between semaglutide treatment and those deaths. The rates were not meaningfully different between the active and placebo arms.

This is an important distinction. A death that happens during a trial is not the same as a death caused by the medicine. Participants in weight-management trials tend to have significant underlying health conditions; some will die from those conditions regardless of what treatment they receive. Regulators assess whether the medicine itself is the cause, and in Wegovy's case, no such determination was made.

There is a common misconception (usually traced to alarming headlines about GLP-1 medicines broadly) that people are dying from weight-loss injections. It is worth letting that framing go. The evidence, reviewed by the MHRA's Drug Safety Updates and equivalent bodies, does not support it for licensed, clinically supervised use. That is not the same as saying the medicine carries no risk at all.

What serious risks does Wegovy actually carry?

Wegovy's known serious risks are documented in its UK licence and monitored by the MHRA. The most clinically significant are acute pancreatitis and gallbladder disease (including gallstones and cholecystitis). Both can be serious if not treated promptly. In January 2026, the MHRA issued a Drug Safety Update specifically addressing acute pancreatitis across GLP-1 medicines, reinforcing guidance that patients should seek urgent medical attention for severe, persistent stomach pain, particularly if it radiates to the back, with or without vomiting.

Other recognised but less serious risks include a GI-dominated side-effect profile: nausea, vomiting, diarrhoea and constipation are the most common, especially in the first weeks of a new dose. Severe, prolonged vomiting or diarrhoea can cause dehydration, which in vulnerable patients carries its own consequences, another reason dose escalation is managed by a prescriber rather than left to the patient.

Wegovy is a Black Triangle medicine in the UK, meaning it is under additional post-market surveillance. The NHS medicines page for semaglutide sets out the full list of side effects and the circumstances that require urgent care. Reading it before starting treatment is genuinely useful, not merely a formality.

If you are weighing up the safety picture alongside what the treatment might cost, our Wegovy pricing page explains what a legitimate private prescription includes, which is relevant context when considering where to get treatment.

How does post-market safety monitoring work for Wegovy in the UK?

Approval does not end the safety review. For a medicine like Wegovy, the MHRA collects Yellow Card reports from patients and clinicians after every prescription is dispensed. These reports feed into ongoing signal detection, if an unexpected pattern of serious harm emerged, the agency would act quickly, as it has done with other medicines in the past.

Semaglutide has now been prescribed to millions of people globally, first as Ozempic for type 2 diabetes and then as Wegovy for weight management. The sheer scale of post-market experience is now one of the more reassuring aspects of its profile. Large-scale real-world data, alongside the randomised trial evidence, consistently shows that the serious-risk rate is low in patients who are appropriately selected and monitored.

Appropriate selection matters. That is the whole purpose of the prescribing process. Our guide to who Wegovy is suitable for covers the eligibility criteria and the conditions that would make a prescriber cautious or decline treatment, including a history of pancreatitis, certain thyroid conditions, and pregnancy. A prescriber review is not a box-ticking exercise; it is what keeps those risks proportionate.

For a broader look at how semaglutide works and what the evidence base covers, our semaglutide overview brings together the key facts in one place. You can also read about why semaglutide does not work for everyone, a question that touches on both effectiveness and the importance of individual clinical assessment. If you are curious about long-term outcomes, our page on whether people keep the weight off after stopping semaglutide is worth a read too.

When should someone get medical help urgently while on Wegovy?

A few situations require prompt action, not a wait-and-see approach. Severe abdominal pain that does not ease, particularly if it spreads towards the back or is accompanied by vomiting, needs urgent medical assessment the same day, this is the pancreatitis signal. Right-sided pain under the ribcage, especially after eating fatty food, can indicate gallbladder problems and deserves the same urgency.

Signs of a serious allergic reaction (widespread rash, swelling of the face or throat, difficulty breathing) require emergency care immediately. Significant dehydration from prolonged vomiting or diarrhoea, to the point of dizziness, very dark urine or inability to keep fluids down, also warrants a call to 111 or a GP the same day rather than pushing through.

For anything less acute (unusual side effects, questions about a missed dose, concerns about how you are feeling) the right place to start is your prescribing team. At nume, our aftercare runs seven days a week for exactly this reason, and if you have been experiencing unexpected cold sensations or shivering, our page on Wegovy shivers explains what is known about this reported side effect and when to mention it to your prescriber. You can see how our clinical team approaches ongoing support on the clinical team page, and our FAQs cover many of the day-to-day questions that come up during treatment.

Any suspected side effect, whether serious or not, can and should be reported to the MHRA using the Yellow Card scheme at yellowcard.mhra.gov.uk. Patient reports are a genuine part of how post-market safety monitoring works; they are not just a formality.

If you would like to understand whether Wegovy might be clinically appropriate for you, our prescribers carry out a thorough same-day review of every consultation. Start your free consultation and a GPhC-registered prescriber will assess your full picture.